Sahlin S, Ahlberg J, Reihnér E, Ståhlberg D, Einarsson K
Department of Surgery, Danderyd Hospital, Sweden.
Hepatology. 1992 Aug;16(2):320-6. doi: 10.1002/hep.1840160207.
The objective of this study was to investigate cholesterol metabolism in human gallbladder mucosa, especially in relation to hepatic cholesterol metabolism, gallstone disease and treatment with bile acids. Gallbladder mucosa and liver tissue samples were collected in 44 patients undergoing cholecystectomy; 30 had cholesterol gallstones and the rest were stone free. Ten of the gallstone patients were treated with chenodeoxycholic acid and eight received ursodeoxycholic acid, with a daily dose of 15 mg/kg body wt, for 3 wk before surgery. The 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, governing cholesterol synthesis, was considerably lower in the gallbladder mucosa than in liver tissue (28 +/- 6 and 120 +/- 40 pmol/min/mg protein). The acyl coenzyme A:acyltransferase activity in the gallbladder mucosa catalyzing the esterification of cholesterol was, on the other hand, several times higher than corresponding activity in the liver (92 +/- 23 and 11 +/- 2 pmol/min/mg protein). In the presence of exogenous cholesterol, the acyl coenzyme A:acyltransferase activity increased about twofold in the gallbladder mucosa. The acyl coenzyme A:acyltransferase activity of the gallbladder mucosa from untreated gallstone patients was not stimulated further by the addition of exogenous cholesterol. Otherwise, there were no significant differences in acyl coenzyme A:acyltransferase and 3-hydroxy-3-methylglutaryl coenzyme A reductase activities in the gallbladder mucosa of gallstone patients compared with gallstone-free controls. Treatment with chenodeoxycholic and ursodeoxycholic acids did not affect the 3-hydroxy-3-methylglutaryl coenzyme A reductase activity of the gallbladder mucosa but reduced the acyl coenzyme A:acyltransferase activity by 60% to 65%.(ABSTRACT TRUNCATED AT 250 WORDS)
本研究的目的是调查人类胆囊黏膜中的胆固醇代谢,尤其是与肝脏胆固醇代谢、胆结石疾病以及胆汁酸治疗的关系。收集了44例接受胆囊切除术患者的胆囊黏膜和肝组织样本;其中30例有胆固醇结石,其余无结石。10例胆结石患者术前接受鹅去氧胆酸治疗,8例接受熊去氧胆酸治疗,每日剂量为15mg/kg体重,持续3周。调节胆固醇合成的3-羟基-3-甲基戊二酰辅酶A还原酶活性在胆囊黏膜中显著低于肝组织(分别为28±6和120±40pmol/min/mg蛋白)。另一方面,催化胆固醇酯化的胆囊黏膜中的酰基辅酶A:酰基转移酶活性比肝脏中的相应活性高几倍(分别为92±23和11±2pmol/min/mg蛋白)。在外源性胆固醇存在的情况下,胆囊黏膜中的酰基辅酶A:酰基转移酶活性增加约两倍。未治疗的胆结石患者胆囊黏膜的酰基辅酶A:酰基转移酶活性不会因添加外源性胆固醇而进一步受到刺激。此外,与无结石对照组相比,胆结石患者胆囊黏膜中的酰基辅酶A:酰基转移酶和3-羟基-3-甲基戊二酰辅酶A还原酶活性没有显著差异。鹅去氧胆酸和熊去氧胆酸治疗不影响胆囊黏膜的3-羟基-3-甲基戊二酰辅酶A还原酶活性,但使酰基辅酶A:酰基转移酶活性降低60%至65%。(摘要截短至250字)